Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High-Throughput AST System Uses Microchip Technology to Rapidly Analyze Bacterial Samples

By LabMedica International staff writers
Posted on 24 Dec 2024

Bacteria are becoming increasingly resistant to antibiotics, with resistance levels ranging from 20% to 98%, and these levels are unpredictable. More...

Currently, antimicrobial susceptibility testing (AST) takes 48 to 72 hours, which delays treatment and results in patients deteriorating while waiting for the correct medication. Prescribing the wrong antibiotics not only worsens the situation but also contributes to the spread of resistant infections, sepsis, and death. In fact, antimicrobial resistance (AMR) was responsible for over 1 million deaths in 2019, surpassing deaths caused by malaria or AIDS. Now, a new system could significantly speed up AST in hospital labs, improving throughput and reducing labor, all while maintaining workflow efficiency.

iFAST Diagnostics (London, UK) is developing an advanced AST system that utilizes microchip technology to analyze bacterial samples rapidly and accurately. The system works by electrically analyzing thousands of bacteria on a microchip, providing both qualitative and quantitative results with remarkable speed. The process starts with extracting bacteria from a sample and exposing them to a range of antibiotics. After a two-hour incubation, the iFAST reader scans 5,000 individual bacteria, analyzing each sample in under a minute. Based on this analysis, the reader identifies the most effective antibiotic for the clinician to prescribe. The iFAST reader can perform over 25 tests a day, with a cost of GBP 20 per patient, which is more affordable compared to current gold standard methods.

This breakthrough in AST technology from iFAST can deliver results in under three hours for blood samples and four hours for raw urine samples—much faster than the standard 48 to 72 hours. This faster turnaround time allows doctors to begin administering the most effective antibiotic treatment earlier, potentially saving lives in critical situations like sepsis or drug-resistant infections. With antimicrobial resistance being a significant global health challenge, iFAST’s AST platform could have a profound impact on patient care and health outcomes worldwide. Research systems are already available, and UK regulatory approval is expected by the second quarter of 2025.

Related Links:
iFAST Diagnostics 


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.